Brian has over a decade of experience in developing medical products, focusing on technologies that enhance national health security. He worked for 11 years at BARDA (Biomedical Advanced Research & Development Authority), where he led development projects in various programs spanning BARDA’s antibacterial, chemical, radiological/nuclear, and thermal burn portfolios. Several of his projects progressed through clinical stages and received FDA approval. He also contributed to BARDA’s acquisitions through Project BioShield.

Brian was instrumental in creating new investment areas at BARDA, particularly in non-traditional antibacterials, and spent the last six years focusing on antibiotic development to combat antimicrobial resistance. He also served as interim Chief-of-Staff for the BARDA Director in 2017-2018 and played key roles in emergency responses, such as launching a vaccine trial during the Ebola crisis and working on the Operation Warp Speed Plasma Team during the COVID-19 pandemic.

Brian has a Ph.D. in chemistry from Harvard University, where he studied as a National Science Foundation Graduate Research Fellow, and a B.S. in chemistry/medicinal chemistry from the University at Buffalo, graduating with highest honors.